Immunic, Inc

1200 Avenue of the Americas, Suite 200
New York, NY 10036, USA

Phone: +49 89 2080 477 00
Email: info@imux.com

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing, Germany

Phone: +49 89 2080 477 00
Email: info@imux.com

Immunic is a clinical-stage
biopharmaceutical company with a
pipeline of selective oral immunology
therapies focused on treating chronic
inflammatory and autoimmune diseases.
Developing
Selective
Oral Drugs in
Immunology
Immunic Therapeutics
Immunic is developing three orally available
small molecule products: lead development
program, IMU-838, is a selective DHODH
inhibitor; IMU-935 is a selective inverse
agonist of RORγt; and IMU-856 targets the
restoration of the intestinal barrier function.
Three
Products in
Clinical
Development

Advanced Development Pipeline
Our mission is to make new, high-quality,
orally available treatment options with sound
therapeutic efficacy and outstanding safety
and tolerability available to multiple sclerosis
patients, thereby improving the quality
of their lives.
Aiming to Offer
Multiple Sclerosis
Patients New, Safe
& Easy-to-Use

Treatment Options
Treating Multiple Sclerosis
We aim to offer new, efficacious, safe and
well-tolerated treatment options to patients
suffering from ulcerative colitis and other
gastrointestinal disorders in order to improve
patients’ lives by eliminating the debilitating
side effects of these diseases.
Making New,
Convenient,
Oral
Treatment
Options Available
to IBD Patients
Treating Ulcerative Colitis
“My life’s work revolves around leading companies to successfully develop and commercialize therapeutics that vastly improve the lives of patients suffering from debilitating diseases. Demanding excellence is paramount to success.”
Dr. Daniel Vitt

Chief Executive Officer, President and Director

“Beautiful science should be translated into a better life for patients, otherwise, it’s still beautiful, but useless.”
Dr. Hella Kohlhof

Chief Scientific Officer

“It is my passion to work with emerging companies to develop ground-breaking technologies. Dedicated, dynamic teams can achieve a lot together when they share mutual respect and empower each other to bring out their best. Or, as the old African proverb says: If you want to go fast, go alone. If you want to go far, work together.”
Dr. Andreas Muehler

Chief Medical Officer

“My focus is, not only, to review and approve documents but to collaborate with my amazing colleagues in order to make a substantial impact for patients while creating long-term value for our investors and other stakeholders.”
Inderpal Singh

General Counsel

“It is my passion to be a member of an emerging company working with a team of extremely talented people, all focused in the same direction, with the goal of bringing life changing therapies to patients.”
Glenn Whaley

Vice President Finance, Principal Financial and Accounting Officer

“I am truly honored to work with such a high-powered team on the pursuit of exciting new science. We aim to bring novel and meaningful therapeutic options to doctors and their patients with devastating inflammatory and auto-immune conditions. Each of our drug candidates is potentially best-in-class and targets a product profile designed to improve patients’ lives by combining the convenience of oral delivery, with robust efficacy and patient-friendly tolerability.“
Dr. Duane Nash

Executive Chairman

Scroll

Contacts

Questions?
Get in touch.

Immunic Inc, ( Nasdaq: IMUX ) Stock Quote:

Loading data...

Currency in USD. Quote data delayed at least 15 minutes.